A Multidimensional Biomarker Panel for The Early Detection of Parkinson’s Disease
Objective: To explore the potential of a multidimensional biomarker panel integrating motor, non-motor, biochemical, metabolic, genetic, and neuroimaging biomarkers to increase sensitivity and specificity of…Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson’s Disease
Objective: To assess the correlation of CSF DDC levels to DaT-SPECT SBR in PD and iRBD. Background: Raised cerebrospinal fluid (CSF) proteomic biomarker, DOPA decarboxylase…VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease
Objective: Develop a sustained disease modifying gene therapy for treating Parkinson’s disease Background: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons…Dopa Decarboxylase as a Biomarker for Parkinsons Disease and Its Relationship to L-Dopa Influence and Sample Size Estimates
Objective: To evaluate the relationship of CSF DDC with levodopa (L-DOPA) treatment and determine its feasibility as a biomarker in clinical trials based on sample…Dopamine replacement therapy modulates dopa decarboxylase, prolactin and AOC3 levels in Parkinson’s disease
Objective: Investigate the impact of dopamine replacement therapy (DRT) on the serum and CSF proteome of people with Parkinson’s disease (PwPD). Background: New high-throughput technologies…Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease
Objective: Characterize the relationship between foslevodopa/foscarbidopa infusion rate and infusion site reaction (ISR) score in patients with Parkinson’s disease (PD) Background: As PD progresses, motor…Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients
Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…Restoring AADC enzyme synthesis in AADC deficiency: MRI-Guided Delivery of AAV2-hAADC Gene Therapy to the Midbrain
Objective: Evaluate the safety and efficacy of real-time MR-guided delivery of adeno-associated virus serotype 2 (AAV2)-hAADC delivery to the SNc and VTA for the treatment…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.